Bio-catalytic asymmetric synthesis of beta-adrenergic receptor blocker precursor: (R)-2-bromo-1-(naphthalen-2-yl)ethanol


Taşdemir V., Kalay E., DERTLİ E. , Sahin E.

BIOCATALYSIS AND BIOTRANSFORMATION, vol.38, no.6, pp.438-444, 2020 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 6
  • Publication Date: 2020
  • Doi Number: 10.1080/10242422.2020.1768245
  • Title of Journal : BIOCATALYSIS AND BIOTRANSFORMATION
  • Page Numbers: pp.438-444

Abstract

Aromatic alpha-halohydrins, particularly 2-haloethanols as significant precursor of drugs, can easily be converted to chiral beta-adrenergic receptor blockers. Eight strains of Lactobacillus curvatus were tested as biocatalysts for asymmetric reduction of 2-bromo-1-(naphthalen-2-yl)ethanone 1 to 2-bromo-1- (naphthalen-2-yl) ethanol 2. The parameters of the bioreduction were optimized using L. curvatus N4, the best biocatalyst found. As a result, (R)-2-bromo-1-(naphthalen-2-yl)ethanol 2, which can be beta-adrenergic receptor blocker precursor, was produced for the first time in high yield and enantiomerically pure form using biocatalysts. Moreover, the gram scale synthesis was performed and 7.54 g of (R)-2 was synthesized as enantiopure form (enantiomeric excess >99%) in 48 h. The important advantages of this process are that it produces of (R)-2 for the first time in enantiopure form, in excellent yield and under environmentally friendly and moderate reaction conditions. This system is of the potential to be applied at a commercial scale.